Drugs.com - New Drug Approvals

Tevimbra Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE) Mar 04, 2025 -- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA)...

Mar 5, 2025 - 04:26
 0
Tevimbra Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE) Mar 04, 2025 -- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA)...
Read More

Tags:

Previous Article

Balking At Saks Globals’ New Payment Terms, Beauty Brands Weigh Whether To Work ...

Next Article

What’s The Difference Between Millionaire And Billionaire Travel? 

Related Posts

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xa...

Feb 24, 2025  0

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

FDA Approves Journavx (suzetrigine), a First-in-Class T...

Feb 9, 2025  0

FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

FDA Approves Tryngolza (olezarsen) to Reduce Triglyceri...

Feb 9, 2025  0